4-hydroxyphenylglycine has been researched along with etomoxir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Maisch, B; Rupp, H; Rupp, TP | 1 |
| Abozguia, K; Clarke, K; Frenneaux, M; Lee, L | 1 |
| Devarakonda, T; Fang, X; Ma, Y; Salloum, FN; Spiegel, S; Wang, W; Wang, XY; Zhou, H | 1 |
1 review(s) available for 4-hydroxyphenylglycine and etomoxir
| Article | Year |
|---|---|
Modification of myocardial substrate use as a therapy for heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Cardiovascular Agents; Energy Metabolism; Epoxy Compounds; Fatty Acids, Nonesterified; Glycine; Heart; Humans; Myocardium; Oxygen; Perhexiline; Piperazines; Ranolazine; Trimetazidine | 2006 |
2 other study(ies) available for 4-hydroxyphenylglycine and etomoxir
| Article | Year |
|---|---|
Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
Topics: Animals; Carnitine O-Palmitoyltransferase; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression Regulation; Glycine; Heart Failure; Humans; Hypoglycemic Agents; Oxidation-Reduction; PPAR alpha | 2005 |
Functional analysis of molecular and pharmacological modulators of mitochondrial fatty acid oxidation.
Topics: Animals; Energy Metabolism; Epoxy Compounds; Fatty Acids; Female; Glycine; Humans; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mitochondria; Oxidation-Reduction; PPAR alpha; Ranolazine; Trimetazidine | 2020 |